Minoxidil has stronger clinical evidence for hair loss
Improvement of visual functions and fundus alterations in early age-related macular degeneration treated with a combination of acetyl-L-carnitine, n-3 fatty acids, and coenzyme Q10
doi: 10.1038/s42255-024-01113-9 12 TurtonMDO'SheaDGunnIBeakSAEdwardsCMMeeranKet al
The decision follows an incident during Phase III clinical trials where an asymptomatic participant experienced a drug-induced liver injury
Sources Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C Eli Lilly and Company July 23, 2026 A Study of Retatrutide (LY3437943) in Participants With Type 2 Diabetes Mellitus Who Have Obesity or Overweight (TRIUMPH-2) National Library of Medicine April 13, 2026 A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3) National Library of Medicine May 22, 2026,
That is a different target from tirzepatide, which the post describes as acting on appetite regulation and metabolic signaling
